WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...

FDA approves the extended-release Bydureon Pen for the treatment of type 2 diabetes. FDA approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and ...

With a view to improve treatment for diabetes patients through innovative technology, product design and development firm Cambridge Consultants in association with AstraZeneca have developed Bydureon ...

US regulators have given the thumbs-up to AstraZeneca's pre-filled, single-use pen injector version of its long-acting diabetes drug Bydureon. US regulators have given the thumbs-up to AstraZeneca’s ...

If you have type 2 diabetes, your doctor may recommend Bydureon BCise as a treatment. It’s used with a balanced diet and exercise to help manage blood sugar. Bydureon BCise is used in adults and ...

AstraZeneca has received regulatory approval for a single-use pen injector to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence rates and a huge unmet ...

WILMINGTON, Del. — AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an ...

AstraZeneca (AZ) has finally secured US approval for a pen injector version of its once-weekly diabetes drug Bydureon after a delay of more than a year. Bydureon Pen (exenatide) had been due to reach ...

The US Food and Drug Administration (FDA) has approved extended-release exenatide in a pen form for the treatment of adults with type 2 diabetes, according to the manufacturer. AstraZeneca's exenatide ...

SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass., Mar 03, 2011 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today ...

US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...